China's pharmaceutical industry has not yet been significantly affected by the financial crisis

Recently, at the first “China Pharmaceutical Industry Roundtable” held in Shanghai, the development of the business under the financial crisis has become the biggest concern for many pharmaceutical companies attending the meeting. Most companies are more optimistic about the Chinese market. Henry Dumai, chairman of the conference and director of the editorial staff of the Economist Intelligence Unit, predicted that the average growth rate of the Chinese market in the next five years will reach 8%.
Boehner Ingelheim China General Manager Pang Nabo said that the real economy in the United States has been significantly affected by the financial crisis, and the shrinking market may have an impact on the pharmaceutical industry. However, Pangnbo believes that China's pharmaceutical market has not been affected by the crisis from the perspective of market capacity, employment status, and so on.
The shortest bull market in the history of A-shares management inhibits stock index Henry Dumai believes that the Chinese pharmaceutical industry will rapidly develop into the most dynamic market in the world within a few years. "In the next five years, the average growth rate of the Chinese market is forecast to reach 8 %."
RayHill, general manager of consulting business consulting firm Emmys Market Research Consulting Co., Ltd., also said: “The Chinese pharmaceutical industry will continue to be the main growth point for the global pharmaceutical industry. It is estimated that by 2012, the Chinese pharmaceutical market will reach US$50 billion. , ranked fifth in the world."
Full coverage of medical reform is the right choice
For China's ongoing health care reform, Pangnbo believes that the basic policy of full coverage is the right choice. As a company, it is concerned with pricing and reimbursement policies for pharmaceuticals, and whether the pharmaceutical companies engaged in innovation can receive government support. Kang De, the managing director of Bayer HealthCare China, also stated that in China, the need to improve patient education and get more patients to obtain health care services is even more urgent.